Key finding — A single high dose of psilocybin produced large, clinically significant decreases in depressed mood and anxiety that were sustained at the 6-month follow-up in about 80% of participants.
Study at a glance
| Field | Detail |
|---|---|
| Institution | Johns Hopkins University |
| Design | Randomized, double-blind, crossover |
| Sample size | 51 participants |
| Intervention | Single high dose (22 or 30 mg/70kg) vs. very low placebo-like dose, crossover |
| Year | 2016 |
| Condition | Cancer-related depression and anxiety |
| Journal | Journal of Psychopharmacology |
| Evidence | established |
Limitations
Small sample, difficult to fully blind given psilocybin's noticeable effects, and a self-selected population of medically and psychiatrically screened patients.
Editorial note
One of the two landmark 2016 trials that re-established psilocybin as a serious subject of clinical psychiatry. Conducted at Johns Hopkins under highly controlled conditions with extensive psychological preparation and support, it remains among the most-cited studies in the field.
Summary written by MMI Editorial for clarity. Always consult the primary source for full methodology and results. The confidence rating reflects our assessment of evidence strength.